TYMP

Thymidine phosphorylase · P19971 · TYMP on Sugi Atlas →

20,266 patent compounds predicted against TYMP, 7,612 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL1682940)	0.59	20/20
SCHEMBL1682930	0.58	20/20
Hydrochloric Acid (SCHEMBL1691080)	0.56	20/20
Hydrochloric Acid (SCHEMBL1691079)	0.51	20/20
SCHEMBL1690954	1.00	19/20
SCHEMBL475093	0.61	19/20
SCHEMBL1682928	0.62	18/20
Tipiracil (SCHEMBL1682924)	1.00	17/20
Hydrochloric Acid (SCHEMBL1682937)	0.72	17/20
SCHEMBL1682926	0.59	17/20
SCHEMBL1690698	0.51	17/20
Hydrochloric Acid (SCHEMBL1690734)	0.51	17/20
Tipiracil (SCHEMBL1682960)	1.00	16/20
SCHEMBL1682944	0.65	16/20
SCHEMBL1682985	0.63	16/20
SCHEMBL1582400	0.51	15/20
Hydrochloric Acid (SCHEMBL1682955)	1.00	14/20
Hydrochloric Acid (SCHEMBL1691104)	0.68	14/20
SCHEMBL918560	0.60	14/20
SCHEMBL1064717	0.59	14/20

Clinical trials — most relevant to TYMP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM	PHASE3	COMPLETED
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.	PHASE3	COMPLETED
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers	PHASE2	WITHDRAWN
Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy	PHASE2	WITHDRAWN
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers	PHASE2	COMPLETED
Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis	PHASE2	UNKNOWN
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene	PHASE2	COMPLETED
Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma	PHASE2	UNKNOWN
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)	PHASE2	UNKNOWN
Thiopurine EnhAnced Maintenance Therapy	PHASE1/PHASE2	COMPLETED
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	COMPLETED
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer	PHASE2	COMPLETED
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)	PHASE2	COMPLETED
Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer	PHASE2	COMPLETED
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver	PHASE2	COMPLETED
A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma	PHASE2	UNKNOWN
A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa	PHASE1/PHASE2	COMPLETED
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Irinotecan and Capecitabine in Treating Patients With Solid Tumors	PHASE1	COMPLETED
MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study	PHASE1	WITHDRAWN
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Study of GS-5319 in Adults With Solid Tumors	PHASE1	RECRUITING
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML	PHASE1	UNKNOWN
The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)	nan	RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TYMP binder may also engage these)

Protein	Name	Similarity
Q5FVR2	—	0.992	Q5FVR2 →
Q99N42	—	0.992	Q99N42 →
Q8IVS8	—	0.971	Q8IVS8 →
TARS2	Threonine--tRNA ligase, mitochondrial	0.967	landscape →
Q86U10	—	0.966	Q86U10 →
Q8VCZ9	—	0.965	Q8VCZ9 →
Q9BE01	—	0.964	Q9BE01 →
Q2V057	—	0.964	Q2V057 →
Q3UQ84	—	0.962	Q3UQ84 →
O95396	—	0.962	O95396 →
Q9UF12	—	0.962	Q9UF12 →
A5GFZ6	—	0.962	A5GFZ6 →
Q5JTZ9	—	0.962	Q5JTZ9 →
Q9HAB8	—	0.961	Q9HAB8 →
Q8BW00	—	0.961	Q8BW00 →
Q0VGK3	—	0.960	Q0VGK3 →
Q68FW7	—	0.960	Q68FW7 →
Q86Y79	—	0.960	Q86Y79 →
A0JNU3	—	0.959	A0JNU3 →
Q8QZY2	—	0.959	Q8QZY2 →
Q8R123	—	0.959	Q8R123 →
TKFC	Triokinase/FMN cyclase	0.959	landscape →
A1A4L8	—	0.958	A1A4L8 →
P85971	—	0.958	P85971 →
Q9BSH5	—	0.958	Q9BSH5 →
Q6MG21	—	0.958	Q6MG21 →
Q2YDP8	—	0.957	Q2YDP8 →
Q5PQQ1	—	0.957	Q5PQQ1 →
ABHD11	sn-1-specific diacylglycerol lipase ABHD11	0.957	landscape →
Q58D08	—	0.957	Q58D08 →